MIRM (Mirum Pharmaceuticals Inc.) stock: $91.83, $5.96B market cap, $438.3M cash, $5.52B EV, $6.70B fully diluted market cap. Next expected readout: Oct-26. Lead program: Maralixibat (Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC)), Phase 3. Data from Fully Diluted's biotech stocks database.
Pipeline assets
Maralixibat (LIVMARLI)
Approved · Active Modality: oral ileal bile acid transporter (IBAT) inhibitor
Target IBAT
Partnerships Shire/Takeda: exclusive worldwide royalty-bearing license (Livmarli, volixibat); Takeda: Japan license for Livmarli (ALGS, PFIC, BA); multiple distributor/license agreements in other territories
Indications- Cholestatic pruritus in Alagille syndrome (ALGS) (Stage not disclosed)
- Cholestatic pruritus/PFIC in progressive familial intrahepatic cholestasis (Stage not disclosed)
- Pruritus in other rare cholestatic settings (EXPAND) (Phase 3)
Status note Approved for ALGS and PFIC cholestatic pruritus in US and EU (also Canada, Japan). EXPAND Phase 3 exploring additional rare cholestatic settings.
Volixibat
Phase 2 · Active Modality: oral, minimally-absorbed IBAT inhibitor
Target IBAT
Partnerships Shire/Takeda: exclusive worldwide royalty-bearing license (milestones + tiered royalties)
Indications- Primary sclerosing cholangitis (VISTAS Phase 2b) (Phase 2)
- Primary biliary cholangitis (VANTAGE Phase 2b) (Phase 2)
- Chronic HDV infection (AZURE program) (Phase 3)
Catalysts- — H2 2026
- — H2 2026
- — H1 2028
Status note FDA Breakthrough Therapy and Orphan Drug designation for cholestatic pruritus in PBC. VISTAS Phase 2b in PSC completed enrollment Q3 2025 with topline expected Q2 2026.
Brelovitug
Phase 3 · Active Modality: fully human monoclonal antibody
Aliases BJT-778
Target hepatitis B surface antigen
Partnerships Bluejay Therapeutics: acquired January 23, 2026; Novartis: worldwide license (up to $4.0M development milestones, up to $27.0M commercial milestones, mid-single-digit royalties)
Indications- Chronic hepatitis delta virus infection (Phase 3)
Status note FDA Breakthrough Therapy designation; EMA PRIME scheme designation; European Commission orphan medicinal product designation. Global AZURE clinical program ongoing (AZURE-1 and AZURE-4 support US registration; AZURE-2 and AZURE-3 support EU registration).
MRM-3379
Phase 2 · Active Modality: oral, CNS-penetrant PDE4D inhibitor
Target PDE4D
Partnerships Enthorin Therapeutics / Dart Neuroscience: worldwide license (Oct 2024)
Indications- Fragile X syndrome (Phase 2)
Status note BLOOM Phase 2 dose-ranging study currently enrolling.
Zilurgisertib
Stage not disclosed · Active
Target ALK2
Indications- Not disclosed (Stage not disclosed)
Status note Named as a clinical-stage product candidate in the development pipeline; no further details in the filing excerpts.
Cholbam (cholic acid)
Approved · Active Modality: oral capsule
Indications- Bile acid synthesis disorders; peroxisomal disorders (PBD-ZSD) (Stage not disclosed)
Status note Commercialized in the US through one specialty pharmacy.
Ctexli (chenodiol)
Approved · Active Modality: oral tablet
Indications- Cerebrotendinous xanthomatosis (CTX) (Stage not disclosed)
Status note Standard of care in the US for CTX; commercialized through one specialty pharmacy.
Per-asset detail extracted from the 10-Q filed 2026-08-05. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.